Kornimate/medical-research-clean huggingface dataset:
irradiated donor lymphocytes in treating patients with metastatic kidney cancer

Conditions: Kidney Cancer

Summary: rationale: when irradiated donor lymphocytes are infused into the patient they may help the patient's immune system kill tumor cells. purpose: this phase ii trial is studying the side effects and how well giving irradiated donor lymphocytes works in treating patients with metastatic kidney cancer.

objectives: * determine the response rate in patients with metastatic renal cell carcinoma treated with hla-partially matched related donor lymphocytes. * determine the rate and kinetics of clinical/radiological response in patients treated with this regimen. * determine the toxicity of this regimen in these patients. * determine the rates of graft-vs-host disease in patients treated with this regimen. outline: patients receive irradiated donor lymphocytes iv over 1 hour on day 0. treatment repeats every 8-16 weeks for up to 6 donor lymphocyte infusions in the absence of disease progression or unacceptable toxicity. blood is collected periodically for research studies, including immunophenotypic analysis of cells and assay for cytotoxic t-lymphocytes and natural killer-cell activity against target cells. after completion of study treatment, patients are followed for 60 days. projected accrual: a total of 35 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * diagnosis of clear cell renal cell carcinoma * metastatic disease * measurable disease * previously treated with high-dose aldesleukin or not eligible for or refused such therapy * no brain metastases by mri or ct scan * hla-partially matched (e.g., ≥ 2/6 hla a, b, dr match) related donor available * patients who have no partially matched immediate family member available are eligible if they have a fully hla-matched donor patient characteristics: * ecog performance status 0-1 * bilirubin ≤ 2 times upper limit of normal * creatinine clearance ≥ 40 ml/min * ast ≤ 3 times uln * cardiac ejection fraction ≥ 45% * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: * see disease characteristics

Keywords: recurrent renal cell cancer clear cell renal cell carcinoma stage iv renal cell cancer
kinesiophobia in patients with fibromyalgia syndrome and chronic neck pain

Conditions: Fibromyalgia; Neck Pain; Healthy

Summary: kinesiophobia which is described as fear of movement reduces physical activity levels and increases the risk of chronic pain. the investigators consider that kinesiophobia levels are higher in patients with fibromyalgia syndrome and chronic neck pain so that physical activity levels are lower in this patient groups. because there are not enough studies, the investigators aimed to evaluate kinesiophobia and physical activity levels in this patients.

objective: to evaluate pain, kinesiophobia, physical activity, depression, disease severity, and fatigue in patients with fibromyalgia syndrome or chronic neck pain and healthy controls. design: cross-sectional study. setting: tertiary health care center, aksaray, turkey participants: 30 patients with fibromyalgia syndrome (group 1), 30 patients with chronic neck pain (group 2), and 30 healthy individuals (group 3) were included. main outcome measures: outcome measures were visual analogue scale (vas)-pain and fatigue, tampa scale of kinesiophobia (tsk), beck depression inventory (bdi), international physical activity questionnaire (ipaq) short form, fibromyalgia impact questionnaire (fiq), neck pain disability index (npdi).

Eligibility criteria:
inclusion criteria: participants with a clinical diagnosis of fibromyalgia syndrome participants with a clinical diagnosis of chronic neck pain healthy participants participants with fibromyalgia syndrome and chronic neck pain has had a disease duration more than three months exclusion criteria: malignant disease systemic infectious disease rheumatic disease operation pregnancy psychological or cognitive disorder history of physical therapy within the last three months history of intra-articular or intra-ligamentary injection within the last three months

Keywords: kinesiophobia physical activity disability
laser ablation of papillary thyroid microcarcinoma

Conditions: Papillary Thyroid Microcarcinoma; Thyroid; Thyroid Cancer

Summary: the purpose of this study is to explore whether percutaneous laser ablation (pla) is a safe and effective alternative to removing papillary thyroid microcarcinoma (ptmc) with surgery.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * papillary thyroid cancer documented by * (a) bethesda vi cytology, * (b) bethesda iii, iv, v, or vi cytology and braf v600e mutation, or * (c) bethesda v cytology and high risk ultrasonographic features documented by either the ata high suspicion or tirads 5 nodule characteristics to ensure the majority of cases will be eligible based on criteria (a) or (b), we will enroll ≤ 2 patients based on criteria (c). * maximum diameter ≤ 13 mm * declined active surveillance * the thyroid lesion must be primarily solid with ≤ 25% cystic compent * no us evidence of extrathyroidal extension through the thyroid capsule * no imaging evidence of lymph node metastasis * preserved contralateral vocal cord function prior to pla exclusion criteria: * thyroid cancer that is non papillary thyroid cancer (ptc) * thyroid lesion with \> 25% cystic component * lesion with us evidence of extrathyroidal extension through the thyroid capsule * clinical or ultrasonographic evidence of lymph node metastasis * pregnancy

Keywords: ptmc papillary thyroid microcarcinoma thyroid cancer percutaneous laser ablation pla 19-438 memorial sloan kettering cancer center
magnetic resonance spectroscopic imaging study of prostatic fats to distinguish the difference between high and low risk prostate cancer

Conditions: Prostate Cancer

Summary: a prostate cancer diagnosis starts a list of events that often leads to fast-moving treatment, thought by many to result in vast over-treatment of this disease. so, discovery of different diagnostic methods that allow clinicians to identify slow-growing from potentially fast-growing disease prior to or at the time of prostate biopsy could result in early and suitable treatment for men at greatest risk, while greatly decreasing the number of biopsies, surgical procedures, hormonal and chemotherapeutic treatments, cost, and patient worry, for those with more slow-growing disease.


Eligibility criteria:
inclusion criteria: * prostate cancer diagnosis prior to treatment * age 21 years or older * signed informed subject consent * prostatectomy as planned prostate cancer treatment exclusion criteria: * men who do not choose prostatectomy * men who have undergone any neoadjuvant therapy * men who have cardiac pacemakers or other implanted electronic devices * men who have any surgically implanted metal * men who have had any surgical procedure that precludes placement of endorectal probe * indication of dementia or memory issues listed on problem list * men who indicate exposure to ocular metal fragments; confirmed by positive ocular x-ray * men who are taking newly-prescribed (within 6 months of enrollment) lipid control medications

Keywords: prostate cancer aggressiveness magnetic resonance imaging fatty acid synthase
effect of pharmaceutical consultations just before rheumatology consultations on improving knowledge and skills for patients with inflammatory arthritis with subcutaneous biologic dmards

Conditions: Arthritis, Rheumatoid; Spondyloarthritis; Biological Therapy

Summary: there is a lack of knowledge among patients concerning their treatment with bdmards. to increase knowledge and safety skills, patient education is essential. the aim of this study is to assess the impact of a pharmacist's educational interview on on knowledge and safety skills to bdmards in patients with inflammatory arthritis.

this is an observational, controlled, open-label and monocentric study. 60 patients are planned to be included. knowledge are assessed three time by self-administered questionnaire: at baseline before the pharmacist's educational interview at three months apart at six months apart one primary end-point is defined: the changes from baseline to m3 and m6 in the patients' knowledge score about subcutaneous bdmard management (self-administered questionnaire, biosecure) as secondary end-points, the changes from baseline to m3 and m6 in patients' adherence, patients' satisfaction regarding the pharmacists' intervention and the effect of the interview on rate of patients treated by biosimilar are evaluated.

Eligibility criteria:
inclusion criteria: * patients must be able to understand and communicate in french and comply with the requirements of the study and must give his agreement (non-opposition) before any study assessment is performed. * patient at least 18 years of age * patient with inflammatory arthritis (rheumatoid arthritis or ankylosing spondylitis or other) * admission in medical consultation in the rheumatology department * patient treated with subcutaneous biologic dmards (tocilizumab, adalimumab, etanercept, golimumab, certolizumab, abatacept, sarilumab, ustekinumab, ixekizumab, anakinra) exclusion criteria: * any medical or psychiatric condition which, in the investigator's opinion, would preclude the participant from completing the study per protocol

Keywords: knowledge safety skills pharmaceutical consultation
imiquimod versus photodynamic therapy of actinic keratoses in organ transplant recipients

Conditions: Actinic Keratoses

Summary: the purpose of this study is to compare two different therapies for actinic keratoses in organ transplant recipients with regard to efficacy and tolerability. the investiagtors are planning to examine treatment with imiquimod 5% cream versus treatment with methyl-aminolaevulinate 16% cream and subsequent irradiation with red light, so-called photodynamic therapy, in this patients' group. a secondary objective of our study is to investigate the reduction in the field cancerisation after both treatments using fluorescence diagnostic method and digital imaging.

organ transplant patients (otp) require lifelong immunosuppressive therapy and consequently are prone to develop skin tumors, i.e skin cancer is the most frequent malignancy in organ transplant recipients. otp frequently develop extensive areas of actinic damage, epidermal dysplasia, wich accounts for increased risk of aggressive skin cancer development in susceptible patients, and are referred to as "field cancerisation". therefore the whole area of field cancerisation has to be treated. in our study we will treat this areas with two different methods and not only the single visible lesions of actinic keratoses.in this open prospective randomized intraindividual study one half of the patients' scalp or face will be treated with imiquimod 5% cream for 4 weeks, 3 times a week, and the other half with methyl-aminolaevulinate 16% cream photodynamic therapy, two applications in two weeks interval. the pre- and post treatment extension of field cancerisation will be assessed by means of a highly sensitive digital fluorescence imaging system.

Eligibility criteria:
inclusion criteria: * age 18 years or older * patients who had received a kidney, liver, lung or heart transplant more than 3 years prior to inclusion into the study * patients who had been treated at least 6 months prior to study entry with a stable twofold or threefold immunosuppressive treatment * patients who had clinically confirmed epithelial dysplasia (actinic keratoses) in at least two anatomically separated contralateral areas on the face and/or scalp with comparable size and extension and minimum distance of 5 cm exclusion criteria: * invasive squamous cell carcinoma or basal cell carcinoma in the treatment area * known allergy to imiquimod and/or methyl-aminolaevulinate and/or one of the other components of the investigational products and/or peanut oil * patients who have received retinoids, interferons or investigational drugs within 4 weeks of study initiation * patients who are participating in othe dermatological study * persistent hepatitis b or c infections * any evidence of systemic cancer * patients who have received any systemic cancer chemotherapy or radiation therapy * pregnant or lactating women * patients

Keywords: actinic keratoses organ transplant recipients photodynamic therapy imiquimod
effect of apolipoprotein e on the prognosis of patients with intracerebral hemorrhage

Conditions: Intracerebral Hemorrhage

Summary: the purpose of this observational study was to compare perihematomal edema and short-term prognosis in patients with intracerebral hemorrhage carrying the apoe-ε3 and apoe-ε4 genes. the main questions it aims to answer are: * exploring whether patients carrying the apoe-ε4 gene have more perifocal perihematomal edema after intracerebral hemorrhage than patients with the apoe-ε3 gene. * apoeε4 gene has worse short-term prognosis than apoeε3 gene in intracerebral hemorrhage patients. all the patients in this study received the same medications based on the guidelines for the management of hypertensive intracerebral hemorrhage.some ich patients were evaluated for stereotactic minimally invasive surgery (smis) treatment by two experienced neurosurgeons.


Eligibility criteria:
inclusion criteria: * relevant diagnosis of supratentorial ich was confirmed through unenhanced ct scanning. * patients were distinguished based on venous blood collection, with the presence of the apoe-ε4 (ε2/ε4, ε3/ε4, ε4/ε4) gene (apoe-ε4 genotype) and patients harboring the apoe-ε3 (ε3/ε3) gene (non-apoe-ε4 genotype). exclusion criteria: * patients with infratentorial ich. * patients with apoe-ε2 (ε2/ε2) based on venous blood collections. * younger than 18 years of age. * ich caused by trauma, anticoagulation therapy, or antiplatelet therapy. * patients admitted to the hospital with diseases that might impact inflammatory responses, such as infective meningitis and systemic infections. * patients with previous residual neurological deficits following a stroke. * patients with combined tumours, severe liver and kidney dysfunction, cardiac insufficiency.

Keywords: intracerebral hemorrhage apolipoprotein e gene perihematomal edema outcome
does text message support after discharge improve outcomes following bariatric surgery? a randomised trial.

Conditions: Obesity; Bariatric Surgery Candidate

Summary: the purpose of this study is to determine whether text message support after discharge from a bariatric service improves outcomes following bariatric surgery.


Eligibility criteria:
inclusion criteria: * all patients who have had a sleeve gastrectomy 18 months ago and are attending the discharge follow-up appointment exclusion criteria: * patients who do not have the ability to receive text messages * patients who do not understand written english

Keywords: bariatric surgery sleeve gastrectomy text messaging weight loss baros follow-up care
etiological diagnosis of traveler's diarrhoea

Conditions: Traveler's Diarrhoea

Summary: traveler's diarrhoea or turista is the most common disease in travelers. it has been reported based on studies in 20 to 60% of travelers, depending among other conditions and travel destinations. currently, less than 30% of the etiology of diarrhoea is identified by bacteriological v,irological and parasitology traditional techniques. this ignorance of the diarrhoea etiology causes difficulties in the establishment of a specific and rapid management in this extremely common condition and having a significant cost to society. technological advances in laboratory diagnosis, such as quantitative real-time polymerase chain reaction (pcr), can allow us now to improve the etiological diagnosis of traveler's diarrhoea using simple rectal swabs. so, the principal objective of this study is to assess the efficacy of a new diagnosis strategy in order to establissh the etiological diagnosis of traveler's diarrhoea. the hypothesis consists in improving the number of patients with a confirmed etiological diagnosis of traveler's diarrhoea by 5%.


Eligibility criteria:
inclusion criteria: * patient leaving for a trip outside france for a period (not exceeding 3 months) * patient who get seen by travel information service at hospital before departure. * adult patients (\> 18 years). * patient who freely signed the written informed consent * patient affiliated to a social security regime. exclusion criteria * minor patient (\<18 years) * pregnant or nursing woman. * adult patient under guardianship. * patient deprivated with liberty under court order. * patient refusing to sign the wrtten consent form

Keywords: turista
association of psychological distress in patients with lung cancer

Conditions: Lung Neoplasms; Psychological Distress; Prognosis Factors; Lifestyle, Healthy; IMMUNOTHERAPY; Targeted Molecular Therapy

Summary: psychological distress is a multi-factorial experience of a psychological, social, spiritual, and/or physical nature that may interfere with one's ability to cope effectively with cancer, physical symptoms and treatment. psychological distress is common and affects the efficacy and prognosis of patients with lung cancer. the systematic anti-tumor therapy may effectively relieve psychological distress including anxiety, depression, and fatigue in patients with advanced lung cancer, the relief of the psychological distress can in turn improve the therapeutic effect. in summary, this study is to explore the associations of (dynamic) psychological stress with the efficacy and survival of anti-tumor therapy including immunotherapy and targeted therapy for advanced lung cancer patients.


Eligibility criteria:
inclusion criteria: * histologically proven diagnosis of lung cancer * 18 years of age or older * ability to understand and the willingness to sign a written informed consent document exclusion criteria: * not willing to participate in this clinical trial
study evaluating neratinib versus lapatinib plus capecitabine for erbb2 positive advanced breast cancer

Conditions: Advanced Breast Cancer; Breast Cancer

Summary: this is a study of an experimental drug (neratinib) versus a combination of drugs (lapatinib and capecitabine) in women who have erbb-2 (her-2) positive metastatic or locally advanced breast cancer. the goal of this study is to compare the two regimens in shrinking tumors and extending the lives of women with erbb2 (her2) positive breast cancer. the study will also compare the safety of the two regimens and to compare quality of life of patients taking the two regimens.


Eligibility criteria:
inclusion criteria: * stage iiib, iiic, or iv erbb2 (her2) positive breast cancer * prior use of herceptin (trastuzumab), and a taxane * adequate cardiac and renal function exclusion criteria: * more than 2 prior herceptin (trastuzumab) regimens or prior use of xeloda (capecitabine) and / or tykerb (lapatinib) \[tyverb\] * bone as the only site of disease * active central nervous system metastases (subjects should be stable and off anticonvulsants and steroids) * significant gastrointestinal disorder with diarrhea as major symptom

Keywords: her2 erbb2 metastatic neratinib lapatinib capecitabine hki-272 nerlynx pb-272
magnetic resonance imaging (mri) in the assessment of head and neck squamous cell carcinoma (hnscc) response

Conditions: Head and Neck Cancer

Summary: the purpose of this study is to see if new techniques of measuring hnscc tumors with magnetic resonance imaging (mri) can help predict how well the tumors will respond to combined chemotherapy and radiation treatment. the investigators hope to find a reliable method to determine whether or not a patient's cancer is responding to chemo-radiation early in their treatment using an mri, such that that cancer treatments could be tailored to the individual more effective in the future. the mri techniques include dynamic contrast-enhanced magnetic resonance imaging (dce-mri), diffusion-weighted magnetic resonance imaging (dw-mri), and magnetic resonance spectroscopy (mrs). participants will be subjected to two sessions of mri scans: one before the initiation of their regular treatment and the second before their second cycle of chemotherapy. each scanning session will last approximately 45 minutes.

dce-mri, dw-mri, mrs have the potential to measure early cellular changes that occur in response to successful therapies, such as chemoradiation, and have been demonstrated to be early predictors not only of therapeutic response, but also of overall survival for other malignancies. our long-term goal is to use these imaging techniques to develop non-invasive functional imaging methodologies that would be better predictors of pathological response than the current clinical standard.

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of loco-regionally advanced (stage iii or iv) squamous cell carcinoma of the head and neck (oropharynx, hypopharynx and larynx) * age \> 18 years * no prior surgery, chemotherapy or radiation therapy for head and neck cancer * scheduled to receive chemoradiation for definitive therapy exclusion criteria: * contraindications to mri (pacemaker, aneurysm clip, mechanical and/or electrical device or metallic fragment, severe claustrophobia) * contraindications to gadolinium * severe, active co-morbidity * major medical illnesses or psychiatric impairments * pregnant or nursing women
acupuncture combined with hydroxychloroquine

Conditions: Primary Sjögren's Syndrome

Summary: to observe the clinical efficacy of acupuncture combined with hydroxychloroquine sulfate tablets on the symptoms of dry mouth and dry eyes in primary sjögren's syndrome.

methods: seventy-two patients with primary sjögren's syndrome who met the inclusion criteria were randomly divided into the experimental group (36 patients, 3 patients who fell out) and the control group (36 patients, 4 patients who fell out). the control group was treated with oral hydroxychloroquine sulfate tablets alone, 0.2g each time, taken twice a day, 4 weeks for 1 course of treatment, a total of 2 courses of treatment, and the experimental group was treated with acupuncture treatment on the basis of the control group, acupuncture once a day, acupuncture for 5 days and 2 days of rest, 4 weeks for 1 course of treatment, a total of 2 courses of treatment. the changes in the outcome indicators of the two groups before and after treatment were observed, and the main outcome indicators included salivary flow rate (sfr) and schirmer test. secondary outcomes included the european league against rheumatism (eular) sjögren's syndrome patient-reported index (esspri), the eular sjögren's syndrome disease activity index (essdai), and laboratory measures (esr, crp, igg).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of primary sjögren's syndrome * must be able to receive acupuncture treatment and swallow tablets exclusion criteria: * patients with malignant tumors or severe organ function impairment * patients who are lactating or pregnant. * persons who are participating in clinical trials of other drugs.